A Silent Attacker SARS-CoV-2 - A Review



Read Counter
974

Downloads
561

Citations

Share

Article Sidebar

Submitted 2020-04-28
Published 2020-05-17
10.24018/ejmed.2020.2.3.246

Read counter = 974 times

Table of Contents

Article Main Content

The recent coronavirus (known as COVID-19 or SARS-CoV-2) has created a pandemic of unheard proportions affecting virtually every country and region of the world. As of April 15, 2020 the virus has resulted in over 2 million infections, and over 100,000 deaths and has brought world economic activities to a standstill, and has led to social isolation and massive unemployment with possible economic recessions on an unprecedented scale around the corner. Till now, the virus shows no signs of abatement. Also till now, scientists have not been able to come out with an effective drug or vaccine against the virus. This review attempts to give a comprehensive view of the origin of the virus, the mode of its entry and infecting human beings, and further discusses the possibility of new drugs and vaccines against the virus.

Keywords: COVID-19, SARS-CoV-2, coronavirus, anti-viral drugs, ACE2

References

  1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet, 2020, 395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9.
    DOI  |   Google Scholar
  2. Rahman S, Bahar T. COVID-19: The New Threat. International Journal of Infection, 2020, 7(1):e102184. doi: 10.5812/iji.102184.
    DOI  |   Google Scholar
  3. Worldometer. https://www.worldometers.info/coronavirus/. Accessed on 15th April, 2020.
     Google Scholar
  4. Sahin AR, Erdogan A, Agaoglu PM, Dineri Y, Cakirci AY, Senel ME, Okyay RA, Tasdogan AM. 2019 Novel corona virus (COVID-19) outbreak: A review of the current literature. Eurasian Journal of Medicine and Oncology, 2020; 4(1): 1-7. doi: 10.14744/ejmo.2020.12220.
    DOI  |   Google Scholar
  5. Woo PCY, Huang Y, Lau SKP, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses 2010, 2, 1804-1820; doi:10.3390/v2081803.
    DOI  |   Google Scholar
  6. Kannan S, Ali PSS, Sheeza A, Hemalatha K. COVID-19(Novel coronavirus 2019)- recent trends. European Review for Medical and Pharmacological Sciences, 2020, 24: 2006-2011.
     Google Scholar
  7. McBride R, Marjorie van Zyl, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses, 2014, 6(8): 2991-3018.
    DOI  |   Google Scholar
  8. Rottier P.J.M. (1995), The Coronavirus Membrane Glycoprotein. In: Siddell S.G. (eds) The Coronaviridae. The Viruses. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1531-3_6.
    DOI  |   Google Scholar
  9. Li F. Structure, function and evolution of coronavirus spike proteins. The Annual Review of Virology, 2016, 3, 237-261.
    DOI  |   Google Scholar
  10. Coronavirus: 7 types of human coronavirus https://en.as.com/en/2020/03/27/other_sports/1585319003_056685.html. Accessed on 16th April, 2020.
     Google Scholar
  11. Hassan S, Sheikh FN, Jamal s, Ezeh JK, Akhter A. Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment.Cureus 12(3): e7355. Doi:10.7759/cureus.7355.
    DOI  |   Google Scholar
  12. Wu Y, Ho W, Huang Y, Dong-Yan J, Li S, Shan-Lu L, Liu X, Qiu J, Sang Y, Wang Q, Kwok-Yung Y, Zhi-Ming Z. SARS-CoV-2 is the appropriate name for the coronavirus. The Lancet, 2020, 395(10228): P949-P950. Doi:https://doi.org/10.1016/S0140-6736(20)30557-2.
    DOI  |   Google Scholar
  13. Foley KE. The coronavirus’s survival mechanism is what makes it so dangerous. QUARTZ. https://qz.com/1822554/how-the-coronavirus-tricks-cells-into-a-full-body-invasion/.
     Google Scholar
  14. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science 12, 8 (2020). Doi: https://doi.org/10.1038/s41368-020-0074-x.
    DOI  |   Google Scholar
  15. Clarke NE, Turner AJ. Angiotensine-converting enzyme 2: The first decade. International Journal of Hypertension 2012, V-2012; Art.ID-307315. doi:10.1155/2012/307315.
    DOI  |   Google Scholar
  16. Hamming I, Timens W, Bulthuis M, Lely T, Navis G, Goor HV. Tissue distribution of ACE2 protein, the functional receptor for SARS Coronavirus. Journal of Pathology 2004, 203(2): 631-637.
    DOI  |   Google Scholar
  17. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Annals of Internal Medicine 2020, doi: 10.7326/M20-0504
    DOI  |   Google Scholar
  18. He J, Tao H, Yan Y, Sheng-You H, Xiao Y. Molecular mechanisms of evolution and human infection with SARS-CoV-2. Viruses 2020, 12, 428.
    DOI  |   Google Scholar
  19. Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, Wang X. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res.2017, 27, 119–129.
    DOI  |   Google Scholar
  20. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454.
    DOI  |   Google Scholar
  21. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018, 14, e1007236
    DOI  |   Google Scholar
  22. Gracia-Ramos AE. Is the ACE2 overexpression a risk factor for COVID-19 infection? Archives of Medical Research 2020. doi: 10.1016/j.arcmed.2020.03.011.
    DOI  |   Google Scholar
  23. Jia PH, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray Jr. PB. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. Journal of virology 2005, 79(23): 14614-14621.
    DOI  |   Google Scholar
  24. Adhikari SP, Meng S, Yu-Ju W, Yu-Ping M, Rui-Xue Y, Qing-Zhi W, Sun C, Sylvia S, Rozelle S, Raat H, Zhou H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious diseases of poverty 2020. 9(29). https://doi.org/10.1186/s40249-020-00646-x.
    DOI  |   Google Scholar
  25. Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, He G, Song T, Huang Q, Rong Z, Deng A, Zeng W, Tan X, Zeng X, Zhu Z, Li J, Wan D, Lu J, Deng H, He J, Ma W.. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). bioRxiv 2020; doi: https://doi.org/10.1101/2020.01.25.919787.
    DOI  |   Google Scholar
  26. ] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. The New England Journal of Medicine. 2020. https://doi.org/10.1056/NEJMoa2001316.
    DOI  |   Google Scholar
  27. He Y, Zheng C. Replication and transmission mechanisms of highly pathogenic human coronaviruses. Zheijiang Da Xue Xue Bao YiXue Ban 2020, 49(1). https://www.ncbi.nlm.nih.gov/pubmed/32298055.
     Google Scholar
  28. Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environment International 2020. 139:105730. doi: 10.1016/j.envint.2020.105730.
    DOI  |   Google Scholar
  29. Meselson M. Droplets and Aerosols in the transmission of SARS-CoV-2. The New England Journal of Medivine 2020. doi: 10.1056/NEJMc2009324.
    DOI  |   Google Scholar
  30. Shivhare SB, Lash EG. Chapter114- Immunity at the maternal-fetal interface. Mucosal Immunology (Fourth Edition) 2015, 2: 2231-2250.
    DOI  |   Google Scholar
  31. Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single cell transcriptome study. PLoS One 2020, 15 (4): e0230295. doi: 10.1371/journal.pone.0230295.
    DOI  |   Google Scholar
  32. de Niet A, Waanders BL, Walraven I. The role of children in the transmission of mild SARS-CoV-2 infection. Acta Paediatrica 2020. doi: 10.1111/apa.15310.
    DOI  |   Google Scholar
  33. Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics 2020. https://doi.org/10.1007/s12098-020-03263-6.
    DOI  |   Google Scholar
  34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
    DOI  |   Google Scholar
  35. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020, 395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.
    DOI  |   Google Scholar
  36. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, Zhang Z, Guan W, Ling Z, Jiang R, Hu T, Ding Y, Lin L, Gan Q, Luo L, Tang X, Liu J. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European Journal of Nuclear Medicine and Molecular Imaging 2020, 47(5):1275-1280. doi: 10.1007/s00259-020-04735-9.
    DOI  |   Google Scholar
  37. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatric Pulmonology 2020, 55(5):1169-1174. doi: 10.1002/ppul.24718.
    DOI  |   Google Scholar
  38. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus diseases 2019 (COVID-19). Journal of General Internal Medicine 2020, doi: 10.1007/s11606-020-05762-w.
    DOI  |   Google Scholar
  39. Shoenfeld Y. Corona (COVID-19) time musing: Our involvement in COVID-19 pathogenecies, diagnosis, treatment and vaccine planning. Autoimmunity Reviews 2020, 102538. doi: 10.1016/j.autrev.2020.102538.
    DOI  |   Google Scholar
  40. Kokkinakis I, Selby K, Favrat B, Genton B, Cornuz J. Covid-19 dagnosis: clinical recommendations and performance of nasopharyngeal swab-PCR. Revue Medicale Suisse 2020, 16(689):699-701.
    DOI  |   Google Scholar
  41. Unhale SS, Ansar QB, Sanap S, Thakhre S, Wadatkar S, Bairagi R, Sagrule S, Biyani KR. A review on coronavirus (COVID-19). World Journal of Pharmaceutical and Life Sciences 2020, 6(4): 109-115.
     Google Scholar
  42. World Health Organization. (2020). Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. https://apps.who.int/iris/handle/10665/331329
     Google Scholar
  43. Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat Biotechnol. 2020. [PMID: 32203294] doi:10.1038/d41587-020-00010-2.
    DOI  |   Google Scholar
  44. Prendergast C, Papenburg J. Rapid antigen-based testing for respiratory syncytial virus: moving diagnostics from bench to bedside? Future Microbiol. 2013;8:435-44. [PMID: 23534357] doi:10.2217/fmb.13.9.
    DOI  |   Google Scholar
  45. Cheng MP, Papenburg J, Desjardins M, Kanjilal S4, Quach C, Libman M, Dittrich S, Yansouni CP. Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: a narrative review. Annals of Internal Medicine 2020, doi: 10.7326/M20-1301.
    DOI  |   Google Scholar
  46. Zhang Z, Shen Y, Wang H, Zhao L, Hu D. High-resolution computed tomographic imaging disclosing COVID-19 pneumonia: a powerful tool in diagnosis. The Journal of Infection 2020, pii: S0163-4453(20)30178-X. doi: 10.1016/j.jinf.2020.03.047.
    DOI  |   Google Scholar
  47. World Health Organization 2020. Clinical management of severe acute respiratory infection when COVID-19 is suspected. 13 March, 2020. Reference Number: WHO/2019-nCoV/clinical/2020.4. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
     Google Scholar
  48. National Health Commission of the People’s Republic of China. Notice on the issunance of guidelines of diagnosis and treatment for 2019-nCoV infected pneumonia (version 6). 6 ed; http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml?from=timeline. 2020.
     Google Scholar
  49. Yang Y, Islam SM, Wang J, Li Y, Chen X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): a Review and Perspective. International Journal of Biological Sciences 2020; 16(10): 1708-1717. doi: 10.7150/ijbs.45538.
    DOI  |   Google Scholar
  50. Mitza O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health 2020, DOI:https://doi.org/10.1016/S2214-109X(20)30114-5.
    DOI  |   Google Scholar
  51. Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, Chen W, Wang XF, Zhang WW, Du WJ, Ruan ZW, Hong L. Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019. European Review for Medical and Pharmacological Sciences 2020, 24(6):3390-3396. doi: 10.26355/eurrev_202003_20706.
     Google Scholar
  52. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 2020, 20(4): P400-402.
    DOI  |   Google Scholar
  53. Bizzarri M, Laganà AS, Aragona D, Unfer V. Inositol and pulmonary function. Could myo-Inositol downregulate inflammation and cytokine release syndrome in SARS-CoV-2? European Review for Medical and Pharmacological Sciences 2020, 24(6):3426-3432. doi: 10.26355/eurrev_202003_20715.
     Google Scholar
  54. Tchesnokov PE, Feng JY, Porter DP, Götte M. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019, 11(326). doi:10.3390/v11040326.
    DOI  |   Google Scholar
  55. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020, 30(3): 269-271. doi: 10.1038/s41422-020-0282-0.
    DOI  |   Google Scholar
  56. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et.al. Compassionate use of remdesivir for patients with severe COVID-19. The New England Journal of Medicine 2020, doi: 10.1056/NEJMoa2007016.
    DOI  |   Google Scholar
  57. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends 2020, 14(1):72-73. doi: 10.5582/bst.2020.01047.
    DOI  |   Google Scholar
  58. Moore, N. Chloroquine for COVID-19 Infection. Drug Safety 43, 393–394 (2020). https://doi.org/10.1007/s40264-020-00933-4
    DOI  |   Google Scholar
  59. Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacology Therapy 1993, 57(2-3): 203-235. Doi: 10.1016/0163-7258(93)90056-j.
    DOI  |   Google Scholar
  60. Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949.
    DOI  |   Google Scholar
  61. Jiun-Ji S, Jim-Min F. Development of effective anti-influenza drugs: congeners and conjugates- a review. The Journal of Biomedical Science 2019, 26:84, doi: 10.1186/s12929-019-0567-0.
    DOI  |   Google Scholar
  62. Costanzo M, De Giglio MAR, Roviello GN. SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Current Medicinal Chemistry 2020, doi: 10.2174/0929867327666200416131117.
    DOI  |   Google Scholar
  63. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et.al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. The New England Journal of Medicine 2020, DOI: 10.1056/NEJMoa2001282.
    DOI  |   Google Scholar
  64. Baden LR and Rubin EJ. Covid-19 — The search for effective therapy. The New England Journal of Medicine 2020 Mar 18; [e-pub]. (https://doi.org/10.1056/NEJMe2005477).
    DOI  |   Google Scholar
  65. Kutlu Ö, Metin A. (2020). A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatologic Therapy, e13383. doi:10.1111/dth.13383.
    DOI  |   Google Scholar
  66. Kassi EN, Papavassiliou K A, Papavassiliou AG. (2020). G6PD and chloroquine: selecting the treatment against SARS-CoV-2? Journal of Cellular and Molecular Medicine. doi:10.1111/jcmm.15312.
    DOI  |   Google Scholar
  67. Zhan WQ, Li MD, Xu M, Lu YB. Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report. European Review for Medical and Pharmacological Sciences 2020, 24(6):3385-3389. doi: 10.26355/eurrev_202003_20705.
     Google Scholar
  68. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Research 2020, 178:104791. doi: 10.1016/j.antiviral.2020.104791.
    DOI  |   Google Scholar
  69. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. Published online April 13, 2020. doi:10.1001/jama.2020.6019.
    DOI  |   Google Scholar
  70. Gallagher J. Coronavirus: Are we getting closer to a vaccine or drug. BBC News. https://www.bbc.com/news/health-51665497. Accessed on 20th April, 2020.
     Google Scholar
  71. Ryan J. Coronavirus treatments: hydroxychloroquine, vaccines and drugs for COVID-19. https://www.cnet.com/how-to/coronavirus-treatments-hydroxychloroquine-vaccines-and-drugs-for-covid-19/. Accessed on 20th April, 2020.
     Google Scholar
  72. Medscape. Oxford COVID-19 Vaccine Trial ‘Within Weeks’ : Q&A. https://www.medscape.com/viewarticle/928941. Accessed on 21th April, 2020.
     Google Scholar
  73. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present and future. Stem Cell Reviews and Reports 2020, doi: 10.1007/s12015-020-09973-w.
    DOI  |   Google Scholar
  74. Jo S, Kim S, Shin DH, Kim M.-S. Inhibition of SARS-CoV 3CL protease by flavonoids. Journal of Enzyme Inhibition and Medicinal Chemistry 2020, 35(1):145-151. https://doi.org/10.1080/14756366.2019.1690480.
    DOI  |   Google Scholar
  75. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, Zheng Y et.al. Diagnosis, treatment and prevention of 2019 novel coronavirus infection in children: expert’s consensus statement. World Journal of Pediatrics 2020, DOI: 10.1007/s12519-020-00343-7.
    DOI  |   Google Scholar